Latest News of ADEX
ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
By Yahoo! Finance |
3 weeks ago
CEO Robert Fried clarified that the $6.4 million improvement in net income was due to changes in working capital. Niagen IV doses are priced at $500-$700 and categorized as pharmaceutical grade sales....
When Will ChromaDex Corporation (NASDAQ:CDXC) Turn A Profit?
By Yahoo! Finance |
4 months ago
ChromaDex Corporation is a bioscience company focusing on healthy aging products, with reduced losses as it approaches breakeven. Analysts predict profitability by 2025, expecting 99% annual growth. T...
Here's Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Looks Fair
By Yahoo! Finance |
5 months ago
ChromaDex's shareholders have faced a 67% loss in the past three years, but the EPS has grown by 54%. CEO Rob Fried's compensation seems reasonable, with a salary below the industry median....